| 546 | Humans (MeSH) |
| 441 | COVID-19 (MeSH) |
| 386 | SARS-CoV-2 (MeSH) |
| 338 | Pandemics (MeSH) |
| 250 | Betacoronavirus (MeSH) |
| 203 | Pneumonia, Viral (epidemiology) |
| 198 | Coronavirus Infections (epidemiology) |
| 144 | Female (MeSH) |
| 129 | Male (MeSH) |
| 107 | Pandemics (prevention & control) |
| 107 | Coronavirus Infections (prevention & control) |
| 100 | Pneumonia, Viral (prevention & control) |
| 96 | Adult (MeSH) |
| 84 | Middle Aged (MeSH) |
| 71 | Aged (MeSH) |
| 68 | Pneumonia, Viral (MeSH) |
| 68 | Coronavirus Infections (MeSH) |
| 66 | Coronavirus Infections (diagnosis) |
| 64 | United States (MeSH) |
| 61 | Pneumonia, Viral (diagnosis) |
| 58 | Pneumonia, Viral (transmission) |
| 58 | Coronavirus Infections (transmission) |
| 55 | Coronavirus Infections (virology) |
| 54 | Pneumonia, Viral (virology) |
| 52 | Pneumonia, Viral (therapy) |
| 52 | Coronavirus Infections (therapy) |
| 44 | COVID-19 (epidemiology) |
| 43 | United States (epidemiology) |
| 41 | Risk Factors (MeSH) |
| 41 | Pneumonia, Viral (complications) |
| 41 | Coronavirus Infections (complications) |
| 39 | Adolescent (MeSH) |
| 38 | Young Adult (MeSH) |
| 32 | Child (MeSH) |
| 31 | Coronavirus Infections (drug therapy) |
| 31 | Betacoronavirus (isolation & purification) |
| 30 | Betacoronavirus (pathogenicity) |
| 29 | Surveys and Questionnaires (MeSH) |
| 29 | Coronavirus Infections (psychology) |
| 29 | COVID-19 Testing (MeSH) |
| 29 | Aged, 80 and over (MeSH) |
| 28 | Pneumonia, Viral (psychology) |
| 27 | Animals (MeSH) |
| 26 | Risk Assessment (MeSH) |
| 26 | Pneumonia, Viral (drug therapy) |
| 26 | Coronavirus Infections (immunology) |
| 25 | COVID-19 (prevention & control) |
| 24 | Telemedicine (MeSH) |
| 24 | Practice Guidelines as Topic (MeSH) |
| 24 | Pneumonia, Viral (immunology) |
| 24 | Comorbidity (MeSH) |
| 23 | Retrospective Studies (MeSH) |
| 22 | Betacoronavirus (immunology) |
| 21 | Cross-Sectional Studies (MeSH) |
| 20 | Infectious Disease Transmission, Patient-to-Professional (prevention & control) |
| 20 | Consensus (MeSH) |
| 19 | Severity of Illness Index (MeSH) |
| 19 | Pneumonia, Viral (physiopathology) |
| 19 | Pneumonia, Viral (mortality) |
| 19 | Disease Transmission, Infectious (prevention & control) |
| 19 | Coronavirus Infections (physiopathology) |
| 19 | Coronavirus Infections (mortality) |
| 18 | Pandemics (statistics & numerical data) |
| 17 | Treatment Outcome (MeSH) |
| 17 | Personal Protective Equipment (MeSH) |
| 16 | Telemedicine (methods) |
| 16 | COVID-19 (virology) |
| 16 | Betacoronavirus (genetics) |
| 15 | Time Factors (MeSH) |
| 14 | Societies, Medical (MeSH) |
| 14 | Public Health (MeSH) |
| 14 | Prevalence (MeSH) |
| 14 | Infection Control (organization & administration) |
| 14 | Hospitalization (statistics & numerical data) |
| 14 | COVID-19 Vaccines (MeSH) |
| 14 | COVID-19 (diagnosis) |
| 13 | Hospitalization (MeSH) |
| 13 | Clinical Trials as Topic (MeSH) |
| 12 | Patient Selection (MeSH) |
| 12 | Infant (MeSH) |
| 12 | Health Policy (MeSH) |
| 12 | Health Personnel (MeSH) |
| 12 | Betacoronavirus (drug effects) |
| 12 | Angiotensin-Converting Enzyme 2 (MeSH) |
| 11 | Pneumonia, Viral (pathology) |
| 11 | Peptidyl-Dipeptidase A (metabolism) |
| 11 | Infection Control (methods) |
| 11 | COVID-19 (therapy) |
| 11 | Antiviral Agents (therapeutic use) |
| 11 | Age Factors (MeSH) |
| 10 | Triage (MeSH) |
| 10 | Registries (MeSH) |
| 10 | Infant, Newborn (MeSH) |
| 10 | Health Knowledge, Attitudes, Practice (MeSH) |
| 10 | Global Health (MeSH) |
| 10 | Coronavirus Infections (pathology) |
| 10 | Clinical Laboratory Techniques (methods) |
| 10 | China (epidemiology) |
| 10 | Child, Preschool (MeSH) |
| 10 | COVID-19 (transmission) |
| 10 | COVID-19 (immunology) |
| 10 | COVID-19 (complications) |
| 9 | SARS-CoV-2 (immunology) |
| 9 | Quarantine (MeSH) |
| 9 | Patient Safety (MeSH) |
| 9 | Occupational Exposure (prevention & control) |
| 9 | International Cooperation (MeSH) |
| 9 | Databases, Factual (MeSH) |
| 9 | Coronavirus Infections (blood) |
| 9 | Coronavirus (MeSH) |
| 9 | Communicable Disease Control (methods) |
| 9 | Cohort Studies (MeSH) |
| 9 | Antibodies, Viral (immunology) |
| 9 | Aerosols (MeSH) |
| 8 | Telemedicine (organization & administration) |
| 8 | SARS-CoV-2 (pathogenicity) |
| 8 | Reverse Transcriptase Polymerase Chain Reaction (MeSH) |
| 8 | Prospective Studies (MeSH) |
| 8 | Pneumonia, Viral (blood) |
| 8 | Personal Protective Equipment (supply & distribution) |
| 8 | Occupational Health (MeSH) |
| 8 | Models, Statistical (MeSH) |
| 8 | Incidence (MeSH) |
| 8 | Hydroxychloroquine (therapeutic use) |
| 8 | Health Status Disparities (MeSH) |
| 8 | Disease Outbreaks (prevention & control) |
| 8 | Disease Management (MeSH) |
| 8 | Delivery of Health Care (MeSH) |
| 8 | Coronavirus Infections (genetics) |
| 8 | COVID-19 (psychology) |
| 8 | COVID-19 (mortality) |
| 8 | Attitude of Health Personnel (MeSH) |
| 8 | Antibodies, Viral (blood) |
| 7 | Viral Vaccines (adverse effects) |
| 7 | Survival Analysis (MeSH) |
| 7 | Sensitivity and Specificity (MeSH) |
| 7 | Reproducibility of Results (MeSH) |
| 7 | Pregnancy (MeSH) |
| 7 | Pneumonia, Viral (metabolism) |
| 7 | Physical Distancing (MeSH) |
| 7 | Internet (MeSH) |
| 7 | Intensive Care Units (MeSH) |
| 7 | Immunoglobulin G (blood) |
| 7 | Ethnic Groups (statistics & numerical data) |
| 7 | Disease Models, Animal (MeSH) |
| 7 | Delivery of Health Care (organization & administration) |
| 7 | Cross Infection (prevention & control) |
| 7 | Clinical Laboratory Techniques (statistics & numerical data) |
| 7 | Clinical Laboratory Techniques (MeSH) |
| 7 | China (MeSH) |
| 7 | Cardiovascular Diseases (epidemiology) |
| 7 | California (MeSH) |
| 7 | Betacoronavirus (physiology) |
| 6 | Videoconferencing (MeSH) |
| 6 | Social Media (MeSH) |
| 6 | Sex Factors (MeSH) |
| 6 | SARS-CoV-2 (physiology) |
| 6 | SARS-CoV-2 (isolation & purification) |
| 6 | Risk (MeSH) |
| 6 | Real-Time Polymerase Chain Reaction (MeSH) |
| 6 | Randomized Controlled Trials as Topic (MeSH) |
| 6 | RNA, Viral (genetics) |
| 6 | Prognosis (MeSH) |
| 6 | Pneumonia, Viral (genetics) |
| 6 | Obesity (epidemiology) |
| 6 | Nasopharynx (virology) |
| 6 | Mice (MeSH) |
| 6 | Mental Health (MeSH) |
| 6 | Infection Control (standards) |
| 6 | Healthcare Disparities (MeSH) |
| 6 | Health Services Accessibility (MeSH) |
| 6 | Health Personnel (psychology) |
| 6 | Head and Neck Neoplasms (surgery) |
| 6 | Government Regulation (MeSH) |
| 6 | Forecasting (MeSH) |
| 6 | Elective Surgical Procedures (methods) |
| 6 | Cytokines (immunology) |
| 6 | Coronavirus Infections (metabolism) |
| 6 | Case-Control Studies (MeSH) |
| 6 | California (epidemiology) |
| 6 | COVID-19 (drug therapy) |
| 6 | COVID-19 (blood) |
| 6 | American Heart Association (MeSH) |
| 5 | Vulnerable Populations (MeSH) |
| 5 | Viral Vaccines (immunology) |
| 5 | Socioeconomic Factors (MeSH) |
| 5 | Social Isolation (MeSH) |
| 5 | SARS-CoV-2 (genetics) |
| 5 | Quarantine (psychology) |
| 5 | Quarantine (legislation & jurisprudence) |
| 5 | Public Opinion (MeSH) |
| 5 | Personal Protective Equipment (statistics & numerical data) |
| 5 | Patient Isolation (MeSH) |
| 5 | Pandemics (ethics) |
| 5 | Otolaryngology (MeSH) |
| 5 | Neoplasms (epidemiology) |
| 5 | Needs Assessment (MeSH) |
| 5 | Models, Theoretical (MeSH) |
| 5 | Mass Screening (MeSH) |
| 5 | Magnetic Resonance Imaging (MeSH) |
| 5 | Lung (virology) |
| 5 | Leadership (MeSH) |
| 5 | Italy (epidemiology) |
| 5 | Italy (MeSH) |
| 5 | Internationality (MeSH) |
| 5 | Immunoglobulin G (immunology) |
| 5 | Immunity, Innate (MeSH) |
| 5 | Hydroxychloroquine (adverse effects) |
| 5 | Health Workforce (MeSH) |
| 5 | Europe (MeSH) |
| 5 | Elective Surgical Procedures (statistics & numerical data) |
| 5 | Delivery of Health Care (methods) |
| 5 | Decision Making (MeSH) |
| 5 | Computer Simulation (MeSH) |
| 5 | Communicable Disease Control (organization & administration) |
| 5 | Clinical Decision-Making (MeSH) |
| 5 | Cause of Death (MeSH) |
| 5 | Antiviral Agents (pharmacology) |
| 5 | Angiotensin-Converting Enzyme Inhibitors (therapeutic use) |
| 5 | Algorithms (MeSH) |
| 5 | Alanine (analogs & derivatives) |
| 5 | Advisory Committees (MeSH) |
| 5 | Adenosine Monophosphate (analogs & derivatives) |
| 4 | Virus Internalization (MeSH) |
| 4 | Viral Vaccines (MeSH) |
| 4 | United States Food and Drug Administration (MeSH) |
| 4 | United Kingdom (epidemiology) |
| 4 | United Kingdom (MeSH) |
| 4 | Triage (standards) |
| 4 | Telemedicine (statistics & numerical data) |
| 4 | T-Lymphocytes (immunology) |
| 4 | Stroke (epidemiology) |
| 4 | Stress Disorders, Post-Traumatic (therapy) |
| 4 | Spike Glycoprotein, Coronavirus (immunology) |
| 4 | Risk Assessment (methods) |
| 4 | Research Design (MeSH) |
| 4 | Quarantine (methods) |
| 4 | Practice Guidelines as Topic (standards) |
| 4 | Pneumonia, Viral (diagnostic imaging) |
| 4 | Pandemics (economics) |
| 4 | Outcome Assessment, Health Care (MeSH) |
| 4 | Otolaryngologists (MeSH) |
| 4 | Olfaction Disorders (etiology) |
| 4 | North America (MeSH) |
| 4 | Mobile Applications (MeSH) |
| 4 | Masks (MeSH) |
| 4 | Internship and Residency (MeSH) |
| 4 | Interdisciplinary Communication (MeSH) |
| 4 | Infection Control (MeSH) |
| 4 | Immunoglobulin M (blood) |
| 4 | Hypertension (epidemiology) |
| 4 | Hospitals (MeSH) |
| 4 | Hispanic Americans (statistics & numerical data) |
| 4 | HIV Infections (epidemiology) |
| 4 | Follow-Up Studies (MeSH) |
| 4 | European Continental Ancestry Group (statistics & numerical data) |
| 4 | Ethnic Groups (MeSH) |
| 4 | Emergency Service, Hospital (MeSH) |
| 4 | Electronic Health Records (MeSH) |
| 4 | Elective Surgical Procedures (MeSH) |
| 4 | Education, Medical, Graduate (MeSH) |
| 4 | Disease Susceptibility (MeSH) |
| 4 | Disease Outbreaks (MeSH) |
| 4 | Diagnosis, Differential (MeSH) |
| 4 | Diabetes Mellitus (epidemiology) |
| 4 | Denmark (epidemiology) |
| 4 | Critical Care (methods) |
| 4 | Critical Care (MeSH) |
| 4 | Coronavirus Infections (economics) |
| 4 | Continental Population Groups (statistics & numerical data) |
| 4 | Congresses as Topic (MeSH) |
| 4 | Communication (MeSH) |
| 4 | Communicable Disease Control (legislation & jurisprudence) |
| 4 | Centers for Disease Control and Prevention, U.S. (MeSH) |
| 4 | Cardiovascular Diseases (therapy) |
| 4 | COVID-19 Nucleic Acid Testing (methods) |
| 4 | COVID-19 (genetics) |
| 4 | Antibodies, Neutralizing (immunology) |
| 4 | Angiotensin Receptor Antagonists (therapeutic use) |
| 4 | Alanine (therapeutic use) |
| 4 | African Americans (statistics & numerical data) |
| 4 | Adenosine Monophosphate (therapeutic use) |
| 3 | World Health Organization (MeSH) |
| 3 | Video Recording (MeSH) |
| 3 | Vaccines (MeSH) |
| 3 | Triage (methods) |
| 3 | Tomography, X-Ray Computed (MeSH) |
| 3 | Thoracic Neoplasms (therapy) |
| 3 | Telemedicine (standards) |
| 3 | Systemic Inflammatory Response Syndrome (epidemiology) |
| 3 | Survival Rate (trends) |
| 3 | Surgical Oncology (standards) |
| 3 | Surgical Oncology (organization & administration) |
| 3 | Surgery Department, Hospital (organization & administration) |
| 3 | Surgeons (MeSH) |
| 3 | Students, Medical (MeSH) |
| 3 | Stress Disorders, Post-Traumatic (psychology) |
| 3 | State Government (MeSH) |
| 3 | Spatial Analysis (MeSH) |
| 3 | Social Support (MeSH) |
| 3 | Social Determinants of Health (MeSH) |
| 3 | Smell (MeSH) |
| 3 | Smartphone (MeSH) |
| 3 | Sleep (MeSH) |
| 3 | Single-Cell Analysis (MeSH) |
| 3 | Severe Acute Respiratory Syndrome (epidemiology) |
| 3 | Sequence Alignment (MeSH) |
| 3 | Safety Management (methods) |
| 3 | Safety Management (MeSH) |
| 3 | SARS-CoV-2 (metabolism) |
| 3 | SARS-CoV-2 (drug effects) |
| 3 | SARS Virus (MeSH) |
| 3 | Respiration, Artificial (statistics & numerical data) |
| 3 | Respiration, Artificial (standards) |
| 3 | Respiration, Artificial (MeSH) |
| 3 | Research (MeSH) |
| 3 | Renin-Angiotensin System (drug effects) |
| 3 | Registries (statistics & numerical data) |
| 3 | Receptors, Virus (genetics) |
| 3 | Radiography, Thoracic (methods) |
| 3 | RNA, Viral (isolation & purification) |
| 3 | RNA, Viral (analysis) |
| 3 | Protein Binding (MeSH) |
| 3 | Practice Patterns, Physicians' (MeSH) |
| 3 | Population Surveillance (methods) |
| 3 | Politics (MeSH) |
| 3 | Point-of-Care Testing (MeSH) |
| 3 | Pneumonia, Viral (ethnology) |
| 3 | Pneumonia, Viral (economics) |
| 3 | Peptidyl-Dipeptidase A (genetics) |
| 3 | Patient Care Management (methods) |
| 3 | Patient Acceptance of Health Care (MeSH) |
| 3 | Particle Size (MeSH) |
| 3 | Pandemics (legislation & jurisprudence) |
| 3 | Oxygen Inhalation Therapy (MeSH) |
| 3 | Otolaryngology (education) |
| 3 | Organizational Innovation (MeSH) |
| 3 | Operating Rooms (organization & administration) |
| 3 | Odds Ratio (MeSH) |
| 3 | Neurology (methods) |
| 3 | Neoplasms (therapy) |
| 3 | Mortality (MeSH) |
| 3 | Molecular Diagnostic Techniques (methods) |
| 3 | Models, Molecular (MeSH) |
| 3 | Models, Biological (MeSH) |
| 3 | Mental Health Services (MeSH) |
| 3 | Machine Learning (MeSH) |
| 3 | Lung (physiopathology) |
| 3 | Lung (pathology) |
| 3 | Longitudinal Studies (MeSH) |
| 3 | Logistic Models (MeSH) |
| 3 | Intubation, Intratracheal (methods) |
| 3 | Intersectoral Collaboration (MeSH) |
| 3 | Intensive Care Units (statistics & numerical data) |
| 3 | Inpatients (MeSH) |
| 3 | Influenza, Human (epidemiology) |
| 3 | Inflammation (virology) |
| 3 | Infectious Disease Transmission, Professional-to-Patient (prevention & control) |
| 3 | Infectious Disease Transmission, Patient-to-Professional (MeSH) |
| 3 | India (epidemiology) |
| 3 | Immunosuppressive Agents (therapeutic use) |
| 3 | Immunocompromised Host (MeSH) |
| 3 | Hydroxychloroquine (administration & dosage) |
| 3 | Humidity (MeSH) |
| 3 | Host-Pathogen Interactions (MeSH) |
| 3 | Healthcare Disparities (statistics & numerical data) |
| 3 | Health Surveys (MeSH) |
| 3 | Health Services Accessibility (organization & administration) |
| 3 | Health Resources (MeSH) |
| 3 | Health Communication (MeSH) |
| 3 | Health Care Surveys (MeSH) |
| 3 | Health Behavior (MeSH) |
| 3 | Head and Neck Neoplasms (pathology) |
| 3 | Guidelines as Topic (MeSH) |
| 3 | Geography (MeSH) |
| 3 | Genome, Viral (MeSH) |
| 3 | Forecasting (methods) |
| 3 | Feasibility Studies (MeSH) |
| 3 | Exercise (MeSH) |
| 3 | Evidence-Based Medicine (MeSH) |
| 3 | Europe (epidemiology) |
| 3 | Equipment Design (MeSH) |
| 3 | Epidemiological Monitoring (MeSH) |
| 3 | Electroencephalography (MeSH) |
| 3 | Drug Design (MeSH) |
| 3 | Disinfection (methods) |
| 3 | Delivery of Health Care, Integrated (organization & administration) |
| 3 | Data Collection (methods) |
| 3 | Coronavirus Infections (ethnology) |
| 3 | Coronavirus Infections (diagnostic imaging) |
| 3 | Contact Tracing (methods) |
| 3 | Communicable Diseases, Emerging (epidemiology) |
| 3 | Communicable Disease Control (MeSH) |
| 3 | Combined Modality Therapy (MeSH) |
| 3 | Cognitive Behavioral Therapy (methods) |
| 3 | Clinical Trials as Topic (standards) |
| 3 | Clinical Laboratory Techniques (standards) |
| 3 | Clinical Competence (MeSH) |
| 3 | Canada (MeSH) |
| 3 | COVID-19 Vaccines (immunology) |
| 3 | COVID-19 (pathology) |
| 3 | COVID-19 (ethnology) |
| 3 | Brain (diagnostic imaging) |
| 3 | Blood Donors (MeSH) |
| 3 | Betacoronavirus (metabolism) |
| 3 | Base Sequence (MeSH) |
| 3 | B-Lymphocytes (immunology) |
| 3 | Azithromycin (therapeutic use) |
| 3 | Arrhythmias, Cardiac (therapy) |
| 3 | Appointments and Schedules (MeSH) |
| 3 | Antiviral Agents (adverse effects) |
| 3 | Antiviral Agents (administration & dosage) |
| 3 | Antigens, Viral (immunology) |
| 3 | Angiotensin-Converting Enzyme 2 (genetics) |
| 3 | Ambulatory Care Facilities (statistics & numerical data) |
| 3 | Ambulatory Care (MeSH) |
| 3 | Airway Management (methods) |
| 3 | Air Microbiology (MeSH) |
| 3 | Age Distribution (MeSH) |
| 3 | African Americans (MeSH) |
| 3 | Academic Medical Centers (MeSH) |
| 3 | A549 Cells (MeSH) |
| 2 | Workforce (MeSH) |
| 2 | Wearable Electronic Devices (MeSH) |
| 2 | Visitors to Patients (MeSH) |
| 2 | Virus Replication (drug effects) |
| 2 | Virus Replication (MeSH) |
| 2 | Virus Internalization (drug effects) |
| 2 | Viral Vaccines (standards) |
| 2 | Viral Vaccines (administration & dosage) |
| 2 | Viral Envelope Proteins (genetics) |
| 2 | Veterans (statistics & numerical data) |
| 2 | Veterans (MeSH) |
| 2 | Vaping (epidemiology) |
| 2 | Vaccines, Attenuated (adverse effects) |
| 2 | Vaccination (ethics) |
| 2 | Uveitis (diagnosis) |
| 2 | User-Computer Interface (MeSH) |
| 2 | United States Department of Veterans Affairs (MeSH) |
| 2 | Uncertainty (MeSH) |
| 2 | Tumor Necrosis Factor-alpha (immunology) |
| 2 | Tumor Necrosis Factor-alpha (blood) |
| 2 | Travel (legislation & jurisprudence) |
| 2 | Transcription, Genetic (MeSH) |
| 2 | Tracheostomy (standards) |
| 2 | Tomography, X-Ray Computed (methods) |
| 2 | Time-to-Treatment (MeSH) |
| 2 | Thoracic Neoplasms (mortality) |
| 2 | Thoracic Neoplasms (epidemiology) |
| 2 | Textiles (virology) |
| 2 | Textiles (standards) |
| 2 | Telecommunications (MeSH) |
| 2 | Taiwan (MeSH) |
| 2 | Systemic Inflammatory Response Syndrome (therapy) |
| 2 | Systemic Inflammatory Response Syndrome (immunology) |
| 2 | Students, Medical (psychology) |
| 2 | Stroke (diagnostic imaging) |
| 2 | Stress, Psychological (psychology) |
| 2 | Stress, Psychological (MeSH) |
| 2 | Spike Glycoprotein, Coronavirus (metabolism) |
| 2 | Spike Glycoprotein, Coronavirus (chemistry) |
| 2 | Specimen Handling (methods) |
| 2 | Specimen Handling (MeSH) |
| 2 | Spain (epidemiology) |
| 2 | Societies, Medical (standards) |
| 2 | Societies, Medical (organization & administration) |
| 2 | Social Media (organization & administration) |
| 2 | Social Class (MeSH) |
| 2 | Smoking (MeSH) |
| 2 | Skull Base (MeSH) |
| 2 | Skin Diseases (virology) |
| 2 | Simulation Training (methods) |
| 2 | Severe Acute Respiratory Syndrome (virology) |
| 2 | Seroepidemiologic Studies (MeSH) |
| 2 | Sedentary Behavior (MeSH) |
| 2 | Schools (MeSH) |
| 2 | Safety Management (standards) |
| 2 | Safety Management (organization & administration) |
| 2 | Risk Assessment (statistics & numerical data) |
| 2 | Risk Assessment (standards) |
| 2 | Reverse Transcriptase Polymerase Chain Reaction (methods) |
| 2 | Retina (drug effects) |
| 2 | Respiratory Tract Infections (virology) |
| 2 | Respiratory System (virology) |
| 2 | Respiratory System (metabolism) |
| 2 | Respiratory Distress Syndrome (therapy) |
| 2 | Respiratory Distress Syndrome (physiopathology) |
| 2 | Resource Allocation (ethics) |
| 2 | Resource Allocation (MeSH) |
| 2 | Republic of Korea (epidemiology) |
| 2 | Reference Values (MeSH) |
| 2 | Reconstructive Surgical Procedures (MeSH) |
| 2 | Receptors, Virus (metabolism) |
| 2 | Receptors, Virus (chemistry) |
| 2 | Reagent Kits, Diagnostic (MeSH) |
| 2 | Radiology (MeSH) |
| 2 | Radiography (methods) |
| 2 | Race Factors (MeSH) |
| 2 | ROC Curve (MeSH) |
| 2 | RNA, Viral (metabolism) |
